Abstract: The invention relates to a combination comprising a quinoline compound or its sail, according to general formula (I) and at least one HIV infection therapeutic agent selected from the group consisting of entry inhibitors, reverse-transcriptase inhibitors, strand-transfer inhibitors, protease inhibitors, and maturation inhibitors. Said combination has therapeutic synergy in the treatment of an HIV infection compared with the quinoline compound, or HIV infection therapeutic agent alone.

Abstract: The present invention relates to a method for analyzing the phenotypic characteristics shown by certain virus strains, particularly human immunodeficiency viruses, involving the construction of a recombinant virus obtained by homologous recombination. The present invention also relates a kit comprising the primers, vectors, cell hosts, products and reagents required to carry out PCR amplification, and the products and reagents used to detect a marker, for the implementation of the method according to the invention.

Abstract: A method of analyzing a sample possibly containing an HIV virus, including a) extracting viral RNA in a biological sample that possibly contains an HIV virus; b) reverse transcription of the RNA obtained of (a) and amplification with a first pair of primers to obtain an amplified product of reverse transcription including all or part of at least two successive genes of a genome of an HIV virus; and one or both of c) and d): c) sequencing the amplified product of (b) to establish a genotype of HIV virus present in the sample and identify mutations that may be present in the amplified product; d1) amplifying the product of (b) with a second pair of primers complementary to the first pair of (b) and capable of generating an amplification product that can be inserted by homologous recombination into a retroviral vector that is defective in a region corresponding to the amplified product; d2) homologously recombining the product of (d1) with the defective vector; d3) functionally analyzing the viral proteins coded

Abstract: The present invention relates to a method for analyzing the phenotypic characteristics shown by certain virus strains, particularly human immunodeficiency viruses, involving the construction of a recombinant virus obtained by homologous recombination.

Abstract: The present invention relates to a method for analysing the phenotypic characteristics shown by certain virus strains, particularly human immunodeficiency viruses, involving the construction of a recombinant virus obtained by homologous recombination.

Abstract: The present invention relates to a method for analysing the phenotypic characteristics shown by certain virus strains, particularly human immunodeficiency viruses, involving the construction of a recombinant virus obtained by homologous recombination.

Abstract: The invention provides an in vitro single cycle, recombinant virus assay (RVA) for determining inhibition of HIV replication by a protease inhibitor. The assay comprises transfecting a human epithelial cell line with amplified HIV protease sequences of an HIV virus; an HIV envelope defective molecular clone having a complete deletion of its protease coding sequence as well as two separate deletions in its env gene and a deletion of part of its gag gene; and a plasmid containing HIV envelope coding sequence under the control of a promoter for phenotypic complementation of the envelope defective molecular clone. The transfected cells are cultured in the presence of a protease inhibitor to produce a testable stock of infectious particles that can be used to infect indicator cells containing an indicator gene without amplification of the infectious particles prior to infecting the indicator cells. Accumulation of indicator gene product is a measure of inhibition of HIV replication by the protease inhibitor.

Abstract: The present invention relates to a method for analyzing the phenotypic characteristics shown by certain virus strains, particularly human immnunodeficiency viruses, involving the construction of a recombinant virus obtained by homologous recombination.